MARKET OVERVIEW
The component of a drug that produces the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies, for example, in long term treatments have various active substances that cure different symptoms or act in different ways. API is the potent component in drug formulation and often used with additives or excipients to improve therapeutic efficacy of a medicine. Many pharmaceutial companies develop their API by own or by outsourcing operations. Some common examples of API are, diclofenac, propanolol, methotraxate etc.
MARKET SCOPE
The "Global Active Pharmaceutical Ingredient (API) Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the active pharmaceutical ingredient (API) market with detailed market segmentation by type of synthesis and therapeutic application. The report provides key statistics on the market status of the leading active pharmaceutical ingredient (API) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type of synthesis the market is bifurcated as, biotech and synthetic.
- Based on therapeutic application the market is segmented as, cardiology, oncology, CNS and neurology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and others.
MARKET DYNAMICS
Drivers:
- Significant growth in pharmaceutical & biotechnology companies.
- Growth in R&D activities across the companies to develop novel molecules and APIs.
- Increasing prevalnece of chronic diseases, idiosyncratic diseases and advancements in API production activities.
Restraints:
- Issues such as higher manufacturing costs and time consuming method of API development.
- Unfavorable DPCO guidelines are also expected to restrain market growth.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Active pharmaceutical ingredient (API) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Active pharmaceutical ingredient (API) market in these regions.
IMPACT OF COVID-19 ON ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. But some of the API molecules such as, remdesivir, favipiravir, and other such API have shown promising outcomes against covid-19 infection which has impacted positively on API market growth however, COVID-19 has disrupted all the business and economic activities across the globe which is expected to have some impact on active pharmaceutical ingredient (API) market. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Active pharmaceutical ingredient (API) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Active pharmaceutical ingredient (API) market are anticipated to lucrative growth opportunities in the future with the rising demand for Active pharmaceutical ingredient (API) in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Active pharmaceutical ingredient (API) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Pfizer, Inc.
- Cipla Inc.
- Merck KGaA
- Bristol Myers Squibb
- GlaxoSmithKline plc
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
Non-small Cell Lung Cancer Report Scope
Report Attribute | Details |
---|---|
Market size in 2024 | US$ XX Million |
Market Size by 2031 | US$ XX Million |
Global CAGR (2025 - 2031) | XX% |
Historical Data | 2021-2023 |
Forecast period | 2025-2031 |
Segments Covered |
By Cancer Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















1. GlaxoSmithKline plc
2. F. Hoffmann-La Roche Ltd
3. Novartis AG
4. Eli Lilly And Company
5. AstraZeneca
6. Pfizer Inc.
7. Takeda Pharmaceutical Company Limited
8. ONO PHARMACEUTICAL CO., LTD.
9. Boehringer Ingelheim International GmbH
10. Merck Sharp & Dohme Corp., (Merck & Co., Inc.)


